Home Cart Sign in  
Chemical Structure| 497223-25-3 Chemical Structure| 497223-25-3

Structure of Cenicriviroc
CAS No.: 497223-25-3

Chemical Structure| 497223-25-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cenicriviroc is an oral, dual CCR2/CCR5 antagonist, and displays potent anti-inflammatory and aninfective activity.

Synonyms: TBR-652; TAK-652; CVC

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cenicriviroc

CAS No. :497223-25-3
Formula : C41H52N4O4S
M.W : 696.94
SMILES Code : O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4
Synonyms :
TBR-652; TAK-652; CVC
MDL No. :MFCD28502076

Safety of Cenicriviroc

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Cenicriviroc

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages 10nM, 20nM or 100nM 6 hours To evaluate the effect of CVC on LPS-induced inflammatory response in macrophages. 100nM CVC significantly inhibited LPS-induced TNFα and IL-6 release. PMC6393202
Mouse primary hepatocytes 10nM, 20nM or 100nM 24 hours To evaluate the effect of CVC on CCL2-induced hepatocyte steatosis. CVC down-regulated the fatty acid synthesis gene Fasn and up-regulated the fatty acid oxidation genes Acox-1, Pgc1α, and Ucp-2. PMC6393202

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Acute sclerosing cholangitis model Subcutaneous injection 15 mg/kg body weight Once daily for 5 days Evaluate the effect of CVC on monocyte/macrophage recruitment, liver injury, and fibrosis PMC6098983
Mice Alcoholic liver disease model Subcutaneous injection 15mg/kg body weight Once daily for 6 weeks (prevention cohort) or the last 3 weeks (treatment cohort) To evaluate the preventive and therapeutic effects of CVC on alcoholic liver disease. CVC significantly reduced alcohol-induced ALT elevation, liver steatosis, inflammation and fibrosis markers, and decreased macrophage infiltration and the proportion of proinflammatory Ly6CHi macrophages. PMC6393202
Mice CPI-hepatitis model Oral administration in drinking water 100 mg/kg/day Continuous administration Prevention and treatment of CPI-hepatitis by inhibiting CCR2+ monocyte recruitment to the liver, reducing CD8+ T cell activation and liver injury PMC11002390
Mice Traumatic brain injury model Oral gavage 100 mg/kg Twice daily for 24 hours Significantly ameliorated injury-induced sequelae in the aged TBI animals PMC4835854
C57BL/6J female mice Chronic alcohol feeding model Subcutaneous injection 15 mg/kg body weight Daily for 6 weeks (prevention cohort) or 3 weeks (treatment cohort) CVC treatment abrogated ethanol-induced recruitment of peripheral macrophages and partially reversed microglia activation. Furthermore, CVC treatment decreased alcohol-mediated expression of inflammatory markers. PMC7547498
C57BL/6 mice CCl4-induced liver fibrosis model Intraperitoneal injection 15 mg/kg body weight Preventive model: 4 doses of CVC and 2 doses of CCl4 per week for 6 weeks; Treatment model: 3 weeks of CCl4 followed by 4 doses of CVC and 2 doses of CCl4 per week for another 3 weeks CVC alleviates liver fibrosis by inhibiting hepatic accumulation of FSCN1+ macrophages and HERC6+ neutrophils and restoring the immune cell landscape PMC10197881
Rats and mice Bile duct ligated (BDL) rats and Mdr2 (Abcb4)−/− mice Gavage 50 mg/kg/day Once daily for 14 days (rats) or 4 weeks (mice) To evaluate the therapeutic effects of CVC alone or in combination with atRA on cholestatic liver injury. Results showed that the combination of CVC with atRA significantly reduced liver to body weight ratio, bile acid pool size, plasma liver enzymes, bilirubin, liver necrosis and fibrosis. PMC6032984

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03059446 Nonalcoholic Steatohepatitis|L... More >>iver Cirrhosis|Non-alcoholic Fatty Liver Disease Less << PHASE2 TERMINATED 2021-01-05 Digestive Health Specialists o... More >>f the Southeast - Dothan, Dothan, Alabama, 36305, United States|Mayo Clinic Hospital, Phoenix, Arizona, 85054, United States|Adobe Clinical Research, LLC, Tucson, Arizona, 85712, United States|Franco Felizarta, MDv, Bakersfield, California, 93301, United States|University of California, San Diego (UCSD), La Jolla, California, 92037, United States|Inland Empire Liver Foundation, Rialto, California, 92377, United States|University of California, San Diego (UCSD) - Medical Center, San Diego, California, 92093, United States|Quest Clinical Research, San Francisco, California, 94115, United States|Upland Clinical Research, Upland, California, 91786, United States|Island View Gastroenterology Associates, Ventura, California, 93003, United States|University of Miami - Schiff Center for Liver Diseases, Miami, Florida, 33136, United States|Advanced Medical Research, Port Orange, Florida, 32127, United States|Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital, Tampa, Florida, 33606, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, 52242, United States|Kansas Medical Clinic PA, Topeka, Kansas, 66606, United States|Delta Research Partners, Llc, Bastrop, Louisiana, 71220, United States|Tandem Clinical Research LLC, Marrero, Louisiana, 70072, United States|Tulane University Medical Center, New Orleans, Louisiana, 70112, United States|Mercy Medical Center - Baltimore, Maryland, Baltimore, Maryland, 21202, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Minnesota Gastroenterology, P.A., Saint Paul, Minnesota, 55114, United States|Digestive Health Specialists, Tupelo, Mississippi, 38801, United States|University of Buffalo - Erie County Medical Center, Buffalo, New York, 14215, United States|Carolinas Medical Center, Charlotte, North Carolina, 28204, United States|Duke University Medical Center (DUMC), Durham, North Carolina, 27710, United States|Wake Research Associates, LLC - Raleigh, Raleigh, North Carolina, 27612, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, 27103, United States|Consultants for Clinical Research - Cincinnati, Cincinnati, Ohio, 45249, United States|Options Health Research, LLC, Tulsa, Oklahoma, 74104, United States|ClinSearch LLC, Chattanooga, Tennessee, 37421, United States|Gastro One, Germantown, Tennessee, 38138, United States|Digestive Health Research, Lebanon, Tennessee, 37090, United States|The University of Texas - Health Science Center & Medical School at Houston, Houston, Texas, 77030, United States|The Texas Liver Institute, San Antonio, Texas, 78215, United States|University of Utah, Salt Lake City, Utah, 84132, United States|Virginia Commonwealth University Medical College of Virginia, Richmond, Virginia, 23249, United States|Virginia Mason Medical Center, Seattle, Washington, 98101, United States|Swedish Medical Center, Seattle, Washington, 98104, United States|Royal Brisbane Hospital and Women's Hospital, Herston, Queensland, 4029, Australia|Central Adelaide Local Health Network Inc - Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Monash Medical Centre, Clayton, Victoria, 3168, Australia|Austin Health, Heidelberg, Victoria, 3084, Australia|UCL Saint Luc Bruxelles, Brussel, 1200, Belgium|University Hospital Erasmus (Brussels), Bruxelles, 1070, Belgium|Antwerp University Hospital (UZA), Edegem, 2650, Belgium|CHU Angers, Angers Cedex 09, 49933, France|Hopital Saint Antoine, Paris, 75012, France|Purpan CHU Toulouse, Toulouse, cedex 9, 31059, France|Uniklinik RWTH Aachen, Aachen, 52074, Germany|Charite - University Hospital Berlin - Campus Virchow - Hospital, Berlin, 13353, Germany|Universitaetsklinikum Hamburg-Eppendorf - I. Medizinische Klinik und Poliklinik, Hamburg, 20246, Germany|Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, 69120, Germany|Uniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, 50937, Germany|Eugastro GmbH, Leipzig, 4103, Germany|University Hospital Giessen and Marburg GmbH, Marburg, 35043, Germany|Prince of Wales Hospital, Shatin, Hong Kong, Hong Kong|Policlinico S. Orsola-Malpighi, Bologna, 40138, Italy|Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milano, 20122, Italy|AOU Policlinico Paolo Giaccone di Palermo, Palermo, 90127, Italy|ID Clinic, Myslowice, 41-400, Poland|Centrum Badan Klinicznych Piotr Napora Lekarze Sp. p., Wroclaw, 50-349, Poland|Fundacion de Investigacion de Diego, San Juan, 927, Puerto Rico|Hospital Universitario Vall d'Hebron, Barcelona, 8022, Spain|Hospital de la Santa Creu i Sant Pau Barcelona, Barcelona, 8026, Spain|Hospital General Universitario Gregorio Maranon, Madrid, 28007, Spain|Nottingham NHS Treatment Centre, Nottingham, NG7 2UH, United Kingdom|Queen Alexandra Hospital, Portsmouth, PO6 3LY, United Kingdom Less <<
NCT03376841 Hepatic Impairment PHASE1 COMPLETED 2017-12-17 Clinical Pharmacology of Miami... More >>, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.43mL

0.29mL

0.14mL

7.17mL

1.43mL

0.72mL

14.35mL

2.87mL

1.43mL

References

 

Historical Records

Categories